Core Viewpoint - The article highlights the significant advancements and potential of the eye surgery robot developed by Disi Medical, which has become the first product to enter the NMPA's "green channel" for innovative medical devices in China, aiming to fill the gap in the commercialization of eye surgery robots in the domestic market [1][3][5]. Group 1: Company Overview - Disi Medical, established in July 2021, focuses on creating intelligent robotic micro-manipulation platforms that exceed human physiological limits [1]. - The company has applied for and authorized dozens of invention patents in China and the United States, and its products have served numerous hospitals, benefiting hundreds of patients with innovative treatments [1][4]. Group 2: Product Development and Clinical Trials - The eye surgery robot has successfully completed domestic clinical trials in several top-tier hospitals and has passed the NMPA's technical review, officially entering the special review process for innovative medical devices [2][3]. - Disi Medical's general micro-surgery robot completed the world's first super-micro-surgery robot-assisted lymphatic-venous anastomosis (LVA) for Alzheimer's treatment in January 2025, showcasing its advanced capabilities [3]. Group 3: Technological Advantages - The micro-surgery robot can achieve precision levels of up to 0.1mm, overcoming limitations posed by human physiological tremors during traditional surgeries, thus significantly enhancing safety and accuracy [3][4]. - The technology is expected to have substantial applications in various fields, including neurosurgery, vascular surgery, plastic surgery, and otolaryngology [5][6]. Group 4: Investment and Market Potential - Disi Medical recently completed nearly 100 million yuan in Series A financing, led by Panlin Capital, with participation from other investors, to accelerate the registration and commercialization of its products [1][5]. - The market for super-micro-surgery robots is viewed as a blue ocean market with high clinical application value, significant technological barriers, and strong market demand [5][6].

Group 1 - The core viewpoint of the news is that Dishi Medical has successfully completed nearly 100 million yuan in Series A financing, which will be used to accelerate the registration and clinical trials of its general microsurgery robot and promote the commercialization of its ophthalmic surgery robot products [1] - Dishi Medical has completed multiple rounds of financing within a year, including Pre-A, Pre-A+, and Pre-A++ rounds, indicating strong investor interest and confidence in the company's growth potential [1] - The company was founded in July 2021 by a team from top institutions and has applied for and authorized dozens of patents in China and the United States, showcasing its commitment to innovation and technology [1] Group 2 - Dishi Medical's ophthalmic surgery robot has completed the first registered clinical trials in several leading hospitals in China and has entered the "green channel" for innovative medical device review, making it the first ophthalmic surgery robot to do so in the country [2] - The general microsurgery robot developed by Dishi Medical successfully completed the world's first robot-assisted lymphatic-venous anastomosis surgery for Alzheimer's treatment, demonstrating its advanced capabilities in microsurgery [2] - The robot can achieve a precision level of 0.1mm in lymphatic and venous anastomosis, significantly improving the safety and accuracy of surgeries compared to traditional methods [2] Group 3 - The founder of Dishi Medical emphasized the rigid demand and clear advantages of microsurgery robots in enhancing stability, precision, and freedom in surgical operations, as well as alleviating surgeon fatigue during long procedures [3] - The company aims to expand the application of robotic microsurgery technology in ophthalmology and microsurgery, providing high-precision, easy-to-operate, and digital solutions for clinical surgeries and life sciences [3] - Dishi Medical is positioned to play a significant role in the future of intelligent robotics, which is expected to revolutionize various fields, including healthcare, agriculture, and industry [3]